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Abstract
Background: Angiopoietins are essential angiogenic mediators. Since inflammatory bowel disease
(IBD) involves inflammation, ulceration and regeneration of the intestinalmucosa, the angiopoietin
system has been proposed as a factor tomaintain pathological angiogenesis during the development
of the IBD.
Aim: To review the potential role of angiopoietins in the inflammation driven by angiogenesis
during the course of the IBD.
Methods: Publications were identified by PubMed searches using the following key words:
angiopoietin; Tie-2 receptor; angiogenesis; inflammatory bowel disease and inflammation, in
various combinations.
Results: Angiopoietin-1 acts as a regulator of blood vessel maturation and has anti-inflammatory
properties, whereas angiopoietin-2 marks the onset of angiogenesis and is required for normal
formation of lymph vessels. Both angiopoietins make use of their angiogenic regulatory effects via
the angiopoietin tyrosine-kinase receptor (Tie-2). While angiogenesis has been shown to promote
and sustain many events of inflammation, the involvement of the angiopoietin system in IBD has
been reported in few studies. It is not clear whether the angiopoietins' role in the development of
intestinal inflammation is due to an imbalance in the levels of these proteins or this system exerts
its pro-angiogenic properties through a different mechanism during the close-loop relationship
between angiogenesis and inflammation.owel disease; CD, Crohn's disease; UC, ulcerative colitis; Ang-1, angiopoietin-1; Ang-2, angiopoietin-2;
eptor; VEGF, vascular endothelial growth factor; EC, endothelial cell; VSMCs, vascular smooth muscle
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184 P.M. Linares et al.Conclusions: Angiopoietins have key functions in the angiogenic process, and their abnormal
activation might depend on their surrounding inflamed environment. The determination of these
angiogenic factors in serum and tissue could be useful for monitoring IBD progression.
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Inflammatory bowel disease (IBD) is a chronic inflammatory
disorder that encompasses two different clinical entities:
Crohn's disease (CD) and ulcerative colitis (UC) 1,2. CD may
affect any part of the gut from the mouth to the anus,
though it is usually located in the terminal ileum and colon.
It is characterized by macroscopic affectation and segmental
distribution along the gut. On the other hand, UC affects the
mucosa of the colon with variable extension from the rectum
to the cecum on a continuous basis.
The etiology of CD and UC remains unclear, but it is
characterized by inflammation located in the gut due to
an altered immune response. Genetic and environmental
factors in the development of both diseases are known to be
involved 3,4.
During the clinical course of both conditions, flare-ups in
activity, characterized by an increase and exacerbation of
inflammation, alternate with remission periods. The number,
frequency and severity of these flares are unpredictable.
Recent investigations have been conducted to elucidate the
etiology of these diseases and the factors that might influence
their evolution.
For instance, IBD is associated with extensive tissue injury
and lymphatic remodeling caused by tissue edema, inflam-
matory cell infiltrates, numerical or functional alteration
of ertain subpopulations of immune cells, loss of epithelial
integrity and increased angiogenesis. These features, together
with the release of cytokines in the intestinal mucosa, might
contribute to the pathogenesis and development of IBD by
triggering diverse molecular mechanisms 5–7. Recently, scien-
tific evidence suggests that vascular development, particularly
lymphangiogenesis and angiogenesis, could play a main role asa cause of IBD tissue injury and not simply an epiphenomenon
ascribed to inflammation 5,8–10.
2. Methods
Bibliographical searches were performed in PubMed from the
earliest records to February 2012 using the following key words
(all fields): (angiopoietin OR Tie-2 receptor OR angiogenesis)
AND (inflammatory bowel disease OR inflammation). The
references from the articles selected for the study were also
examined in search of articles meeting the inclusion criteria.
Relevant abstracts and other material from meetings were
investigated. Studies on angiopoietin function in other diseases
were included if relevant information was reported.
2.1. Angiogenesis
Blood vessels originate through two processes called
vasculogenesis and angiogenesis. Vasculogenesis starts in the
embryonic period from multipotent progenitor cells, while in
angiogenesis the vascular networks are created from the
pre-existing ones. Physiological angiogenesis takes place during
processes like the menstrual cycle, embryonic development,
tissue repair and bone growth.11,12 Angiogenesis is considered
to be activated primarily by hypoxia 7,13. Afterwards, the basal
membrane is degraded by metalloproteases and endothelial
cells (ECs) proliferate, triggered by the released integrins
and adhesion molecules. Finally, pericyte recruitment
stabilizes the newly-formed vessels. Upon stabilization and
structuring of the new microvessel network, the balance
between proangiogenic and antiangiogenic factors in physio-
logical angiogenesis returns to the baseline levels and the
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mediators in pathologic angiogenesis remains augmented and
formation of new vessels persists 14. Altered angiogenesis has
been reported in other inflammatory diseases such as cancer,
atherosclerosis, ischemic heart disease, rheumatoid arthritis
or asthma 12,15,16.
2.2. Cytokines and angiogenesis
As a result of the reciprocal angiogenesis–inflammation
activation processes, there is an increase of proinflammatory
cytokines, chemokines, eicosanoids, thromboxanes and free
radicals in the interstitial medium. Among these released
proteins, the most important angiogenic mediator, VEGF-A,
has recently gained special relevance. For instance, increased
levels of VEGF-A released during active episodes of IBD increase
endothelial expression of intercellular adhesion molecule-1 to
promote enhanced leukocyte adhesion 17. Additional VEGF-A
action increases blood vascular permeability which intensifies
gut edema, a central characteristic of IBD. Finally, new blood
vessels formed in the inflamed gut in response to VEGF-A may
exhibit delayed maturation, displaying incomplete recruit-
ment of pericytes necessary to stabilize vessels, inhibit
endothelial proliferation and reduce vascular leakage 18,19.
Besides the classic angiogenic factors such as VEGF-A, the
angiopoietin Ang/Tie system plays an important and comple-
mentary role in the regression, maturation and stabilization of
blood vessels 20,21.
2.3. Angiopoietin family
Ang-1, Ang-2 and the interspecies orthologs such as Ang-3
(mouse)/Ang-4 (human) are natural ligands of the Tie-2
receptor, which is expressed primarily on ECs and early
hematopoietic cells. The other kinase receptor, Tie-1, is an
orphan receptor that may also act as an angiopoietin receptor,
possibly in complex with Tie-2, but little is known about its
function in angiogenesis 22–29. Angiopoietins do not belong to
the VEGF family, but are also key mediators in angiogenesis.
The Ang/Tie receptor signaling cascades are involved in
fundamental angiogenesis events including vascular stabiliza-
tion and remodeling, as well as recruitment of pericytes and
vascular smooth muscle cells (VSMCs). Ang-1 acts as a regulator
of blood vessel maturation and has anti-inflammatory proper-
ties. Its stimulation in lymphatic ECs promotes up-regulation of
a VEGF receptor – VEGFR-3 – suggesting that it is also indirectly
involved in VEGF-C/VEGFR-3 pathway (Fig. 1). On the other
hand, Ang-2 is particularly responsible for the initiation of
angiogenesis and it is necessary for the normal formation of
lymphatic vasculature 25,28,30–34.
2.4. Angiopoietin-1
The first angiopoietin that was discovered was Ang-1 which
is secreted by pericytes, mesenchyme and VSMCs of the
developing vasculature and it is thought that it stabilizes the
formation of newly formed blood vessels 25,35.
Ang-1 promotes EC cell stability by inducing Tie-2 phos-
phorylation (p-Tie-2) and suppressing endothelial migration,
which enhances survival 25,36–42. It leads to the induction and
maintenance of a ‘quiescent’ phenotype in capillaries. Ang-1also protects against airway inflammation and hyperreactivity
in asthma 43,44, reduces thrombin-induced interleukin-8 pro-
duction and neutrophil adhesion 45, decreases VEGF-induced
up-regulation of inflammatory adhesion molecules 46, pre-
vents endothelial hyperpermeability, thereby maintaining
vessel integrity, and inhibits leukocyte-endothelium in-
teractions 27,30. Ang-1 and VEGF-A are thought to have a
complementary effect on blood vessel growth which could
be due to both ligands being able to activate the receptor
Tie-2 (Fig. 1).
The release of Ang-1 protein from neutrophils differs
from secretion of VEGF-A, because Ang-1 is cytosolic and its
release is neither dependent on calcium, TNF-α nor other
neutrophil-activating cytokines 47. Ang-1 is expressed in the
prostate, skeletal muscle, small intestine, heart, and areas
of the brain 26.
Targeted disruption of Tie-2 or Ang-1 results in embry-
onic lethality, which occurs at a slightly later stage than
that seen in VEGF-A knockout animals 48. However, in the
postnatal vasculature, Ang-1 appears to play a predominant
role in the maintenance of endothelial homeostasis and
prevention of vascular inflammation through the activation
of Tie-2 49.
Ang-1 and Ang-2 have been shown to interact with other
receptors, including integrins 50. Monomeric DeltaAng-1 has
been observed binding α5β1 integrin with similar affinity
compared to Tie-2 (Fig. 1). This suggests that angiopoietins
could be involved in mediating cell adhesion or migration
through integrins independent of the Tie-2 receptor 51.
Moreover, in colonic samples from CD and UC patients,
intestinal lamina propria mononuclear cells CD19+ B cells
expressed more α5 integrin than normal specimens 52.2.5. Angiopoietin-2
Another major factor involved in angiogenesis, and discovered
by sequence homology to Ang-1, was Ang-2 26. The functional
role of Ang-2 is to act as a competitive antagonist of Ang-1 on
ECs and VSMCs. It down-regulates Tie-2 signaling, thereby
releasing the vascular endothelium from the strengthening
inhibitory influence of Ang-1 53.
Ang-2 facilitates EC activation in response to VEGF-A and
other classic growth factors, and a given pathophysiological
condition such as hypoxia 54. It promotes angiogenesis by
allowing ECs to be more responsive to VEGF-A mediated
cell proliferation which is necessary for EC repair and turn
over 38,39,55. In the absence of VEGF-A, Ang-2 destabilizes
the interaction between ECs and their support cells, causing
plasma leakage and promoting vascular regression 26,56–60.
However, recent studies have demonstrated that the
activity of Ang-2 is more complex than previously believed.
When it binds Tie-2 without inducing phosphorylation,
Ang-2 interrupts essential Ang-1/Tie-2 signaling, acting
mainly as a functional antagonist of Ang-1 in an autocrine
way 15,22,23,26,42,61. Such beneficial or detrimental effects
on inflammation depend not only on the phosphorylation of
the Tie-2 receptor, but also on the duration of its particular
receptor binding 37,38,41,62,63.
Ang-2 shows agonist activity binding Tie-2 in the absence of
Ang-1; however, it functions as a dose-dependent antagonist
when Ang-1 is present. ECs produce Ang-2 but not Ang-1, and
Figure 1 Schematic representation of possible Ang/Tie-2 signaling between vascular endothelial and smooth muscle cells and
pericytes. Ang-1 multimers bind to Tie-2 on ECs, induces receptor phosphorylation and behave as an anti-inflammatory cytokine.
Phosphorylated Tie-2 also down-regulates VEGFR-2 expression.When Ang-1 binds Tie-2 without phosphorylation, VEGFR-3 is up-regulated
inducing lymphangiogenesis. Conversely, Ang-2 normally functions as an Ang-1 antagonist andmediates increases in vascular permeability
and primes the vasculature for angiogenesis, but it could also function as a partial Tie-2 agonist under certain conditions: without inducing
phosphorylation, Ang-2 interrupts Ang-1/Tie-2 signaling. In the absence of Ang-1, Ang-2 shows an agonist activity in a dose-dependent
manner, and endogenous Ang-2 maintains Tie-2 activation. Both Ang-1 and Ang-2 can bind α5β1 integrin similarly to Tie-2. Ang-3 and
Ang-4 anchor Tie-2 as agonist and antagonist, respectively, but their exact function remains unclear.
186 P.M. Linares et al.this endogenous Ang-2 maintains EC survival, migration and
tube formation. When these cells are stimulated with Ang-1
and -2, Ang-2 dose-dependently inhibits Ang-1-induced EC
survival. Although Ang-2 is a weaker agonist than Ang-1,
endogenous Ang-2 maintains a level of Tie-2 activation that
is critical to a spectrum of EC functions (Fig. 1) 64,65. This
dose-dependent modulation of Ang-2 activity may be impor-
tant in the regulation of neovessel formation because one
ligand can mediate both the initial inhibition of Tie-2 activity
necessary for an efficient early angiogenic response, as well as
later maturation and stabilization of the neovasculature 28.
This view was challenged by the observation that high level
expression of Ang-2 is present in both highly malignant tumors
such as glioblastoma multiforme and inflammatory conditions
such as psoriasis, IBD and hemangiomas 53,64,66,67.
Ang-2 activates multiple signaling pathways including
reactive oxygen generation. It also plays a role by sensitizing
endothelial cells to tumor necrosis factor (TNF-α) and can
exaggerate inflammatory responses 37,68. In adult human
tissues, Ang-2 expression is largely restricted to sites of active
vascular remodeling such as ovaries, uterus and placenta,
while Ang-1 is more widespread 26.2.6. Angiopoietin-3/Angiopoietin-4
Very little is known about these ligands. Ang-3 is thought to
act as an agonist while Ang-4 exerts an antagonist effect at
the Tie-2 receptor (Fig. 1). Their expression patterns also
differ, as Ang-3 is expressed throughout the body and Ang-4
is detected only in lung 37,69. Currently, the exact biological
actions and pattern of Tie-2 signaling by Ang-3 and -4 are
poorly characterized but their function seems to be cell
specific 33,34.
2.7. Angiopoietins and the lymphatic system
Lymphatic vessels, which drain interstitial fluids, and return
them back to circulation, are thought to grow following blood
capillaries, in order to recover tissue homeostasis 70,71. Ang-2
is known to be involved in the regulation of embryonic
lymphangiogenesis. However, the role of Ang-2 in postnatal
pathological lymphangiogenesis, such as inflammation, is
largely unknown 72.
Although several lymphangiogenic factors are known to be
involved in the formation of lymphatic vessels, the molecular
187Angiopoietins in inflammatory bowel diseasesmechanisms that maintain lymphatic integrity and control the
resolution of inflammation remain unclear. In vitro studies
revealed that, during inflammation, the stability, integrity
and function of lymphatic endothelial cells are enhanced in
the presence of Ang-1 73.
In addition to blood vessel organization, Ang-2 deficiency
also influences the development of lymphatic vessels, partic-
ularly those within the gastrointestinal system 74. In this
respect, Ang-2 deficient mice have been reported as a relevant
model of intestinal lymphatic dysplasia 75.
2.8. Angiopoietins in animal models
Recently, Cho et al. 76 designed an Ang-1 variant, COMP-Ang-1,
which was more potent than native Ang-1 in phosphorylating
the Tie-2 receptor in lung ECs in vivo. After its administration
to mice, it was mainly located in microvascular ECs of the
intestinal villi and lung. The Ang-1 variant prolonged survival in
irradiated mice, showing specific protection against EC injury.
There is evidence that Ang-2 deficient mice show complex
defects in vascular development and postnatal vascular
remodeling 29,77,78. In IBD mouse models, blockade of Ang-2
with L1-10, an Ang-2-specific inhibitor, significantly inhibited
lymphangiogenesis but promoted angiogenesis. These results
clearly indicate that Ang-2 acts as a crucial regulator of
inflammatory lymphangiogenesis by sensitizing the lymphatic
vasculature to inflammatory stimuli, thereby directly promot-
ing lymphangiogenesis 72.
In the development of experimental IBD in Ang-2(−/−) DSS
treated mice, leukocyte infiltration, inflammation and blood
and lymphatic vessel density have been shown to be signifi-
cantly attenuated compared with wild type DSS treated mice.
Ang-2mediates inflammatory angiogenesis, lymphangiogenesis
and neutrophil infiltration to reduce some, but not all clinical
features of IBD.5 However, in DSS induced endoglin heterozy-
gous, Eng(+/−) mice model, Ang-1 and Ang-2 levels remained
unchanged in the distal colon during DSS induction. In contrast,
VEGF-A levels and vascular permeability were increased in the
chronic phase of colitis 8.
2.9. Role of angiopoietins in IBD
Koutroubakis et al. first measured circulating serum levels of
Ang-2 and Tie-2 in patients with IBD 79. Both angiogenic factors
were slightly elevated in patients with CD and UC compared
with controls and Ang-2 also correlated with disease activity.
Significantly higher levels of Ang-2 in patients with active IBD
compared with patients with non-active disease were found.
Both Ang-2 and Tie-2 median serum levels were significantly
higher and lower, respectively, in those patients with early
disease (diagnosis b 2 years) compared with IBD patients with
late disease diagnosis 79. A second study, where Ang-1 levels
were also assessed, supported these observations in CD. In
contrast to what resulted in Ang-2 and Tie-2, levels of Ang-1
were lower in patients with CD compared with healthy controls.
This imbalance between Ang-1 and Ang-2 may reflect an
abnormal process ofmaturation and stabilization of the vascular
network during the course of IBD. Several correlations among
angiopoietins and acute-phase reactants were also found 80.
A later report also suggested that, besides the potential
role of angiopoietin circulating levels as disease markers, theAng/Tie pathwaymay play a role in the local progression of UC
by studying tissue samples from colonic mucosa 81. The
authors found that epithelia of crypt abscesses were strongly
positive for Ang-1 and -2 in samples derived from patients with
active UC, though the colorectal epithelium without crypt
abscess showed minimal expression of Ang-1, Ang-2, and
Tie-2. Specimens from UC patients in remission showed
significantly less immunoreactivity for Ang-1, -2, or Tie-2.
Therefore, they confirmed that the angiogenic response is
induced by Ang-2, in the presence of VEGF-A, blocking the
normal vessel-stabilizing effect of Ang-1 81. These results, the
high immunohistochemical expression of Ang-1 in mucosal
samples from patients with endoscopically-active UC
compared with non-active UC patients, is similar to that
of our group's current investigation. Moreover, we also found a
high microvessel density in the same high Ang-1-expressing
samples from active compared with non-active UC patients.
Nevertheless, we have also included patients with CD, but no
differences in Ang-1 expression and microvessel density were
found when patients with active and inactive CD were
compared 82.
These results concur with those of a large study performed
in IBD patients in which CD patients with disease restricted to
the colon had significantly lower serum Ang-2 levels in
comparison with other phenotype locations, probably due to
a transient variability or heterogeneity of endothelial cell
characteristics 83,84. Additionally, the authors found higher
serumAng-1 levels in UC patientswhowere smokers compared
with non-smokers. This increase of serumAng-1 in smoking UC,
but not in CD, patients may be related to the nicotine effect
on angiogenesis, which is known to up-regulate VEGF 85,86.
This probably suggests a collaboration between the VEGF and
the angiopoietin system in UC which does not occur in CD 80.
On the other hand, no statistically significant difference in
serum Ang-1 and -2 levels related to disease duration or
activity was established, in contrast with previously reported
data for serum Ang-2 83,84.
Recently, Pousa et al. evaluated serum angiopoietin levels
in patients with UC who underwent oral corticosteroid
treatment. At baseline, Ang-1 levels were statistically signif-
icant lower than those in healthy individuals while Ang-2
levels, together with VEGF-A, were higher than in controls. In
the samework, no correlation between angiopoietin levels and
clinical activity of UC was found 87.
In this study, after treatment, patients who achieved
complete remission showed statistically significantly higher
serum levels of Ang-1 and Ang-2, but not of Tie-2, compared
with those that did not achieve remission. Moreover, after
completing treatment, Ang-1 and Ang-2 concentrations nearly
returned to their baseline levels 87. Therefore, corticosteroids
temporarily alter circulating levels of VEGF and angiopoietins.
We are currently studying the effect of anti-TNF-α treat-
ment on angiopoietin levels in patients with IBD. However, in
contrast to the angiopoietin level modification seen during
corticosteroid treatment, we have not observed changes in
the levels of these factors after treatment. Although Ang-2
can mediate inflammation by up-regulating the response of
endothelial cells to TNF-α, the effectiveness of anti-TNF-α
treatment appears to not be related to the changes in the levels
of these angiogenic factors 88.
In addition to the potential of the serum angiopoietin
system levels as optimal markers of clinical activity, we also
188 P.M. Linares et al.evaluated histological and clinical activity. We studied the
angiopoietin system in both serum and culture supernatant of
mucosal samples 89,90. We found that serum Ang-1 levels were
higher in patients with endoscopically active IBD compared
with non-active ones. In culture supernatant, levels of Ang-1,
Ang-2 and Tie-2 were higher in patients with active compared
with non-active IBD and Ang-2 levels of patients in remission
were even lower than in controls. Probably, during periods of
quiescence, lower levels of Ang-2 are released, as the Ang-
2-expressing ECs recruitment ends, but the initial angiogenic
balance is not totally restored. Also, there was a positive
correlation between serum and colonic mucosa culture
supernatant levels of Ang-1. Interestingly, we found differ-
ences of mucosal Tie-2 levels between affected and non-
affected colonic area 89,90.
Ang-1 concentrations were modified in parallel with the
severity of histological lesions, and moderately correlated
with clinical and endoscopic activity. Thus, that the measure-
ment of Ang-1 levels in serum may be useful as a non-invasive
method should be put cautiously, as the area under the
receiver operator Characteristic (ROC) curve for the diagnosis
of disease activity for Ang-1 was below 0.7 for serum levels
and 0.8 for mucosal culture supernatant 89,90. Therefore,
serummeasurement of angiopoietins is not yet completely set
up to avoid unnecessary colonoscopies.3. Conclusions
The angiopoietin system is implicated in the regulation of the
angiogenic process in sustained inflammation. These factors
are also essential for vascular development, maturation and
stability. As IBD is triggered by an activation of the immune
system characterized by a chronic inflammation located in the
gut, disease progression has been shown to be maintained by
angiogenesis in a mutually dependent association. Neverthe-
less, the direct implication of the angiopoietin system in the
development of intestinal inflammation is not fully under-
stood. No less important is that until now, most of the studies
are focused on the determination of these factors at a
circulating level, which present high variability. Taking into
account that cellular function and response depend on the
surrounding environmental protein network, the exploration
of changes in the distribution and association of angiopoietins
with the mucosal activity that defines critical events involved
in the disease's pathogenesis is required. Therefore, larger-
scale studies in patients with IBD are needed to further
determine the exact mechanisms that associate inflammation
and angiopoietin levels.Conflict of interest
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